Trelegy Ellipta Dosage and Formulation for COPD
For adult patients with COPD, Trelegy Ellipta is dosed as fluticasone furoate 100 mcg/umeclidinium 62.5 mcg/vilanterol 25 mcg (100/62.5/25 mcg), administered as one inhalation once daily via the Ellipta dry powder inhaler 1.
Specific Dosing Details
- Single strength for COPD: The 100/62.5/25 mcg formulation is the ONLY strength indicated for COPD treatment 1
- Frequency: Once daily administration at the same time each day
- Maximum frequency: Do not use more than once every 24 hours 1
Administration Technique
After each inhalation, patients should rinse their mouth with water without swallowing to reduce the risk of oropharyngeal candidiasis 1. This is a critical step that should be emphasized during patient counseling.
No Dose Adjustments Required
The standard dose applies across all patient populations—no adjustments are needed for 1:
- Geriatric patients
- Patients with renal impairment
- Patients with moderate hepatic impairment
Clinical Context from Guidelines
The 2023 Canadian Thoracic Society guidelines support single-inhaler triple therapy (SITT) for patients with persistent moderate-to-severe dyspnea despite dual therapy, and particularly for those at high risk of exacerbations, given that SITT reduces mortality in moderate-severe COPD 2. The 2017 GOLD guidelines recommend escalation to LABA/LAMA/ICS (triple therapy) for Group D patients who continue to experience exacerbations on dual bronchodilator therapy 3.
Important Caveats
- Not for acute relief: Trelegy is for maintenance treatment only; patients need a separate short-acting beta2-agonist (e.g., albuterol) for breakthrough symptoms 1
- Contraindicated: In status asthmaticus/acute COPD episodes requiring intensive measures, and in patients with severe hypersensitivity to milk proteins or any component 1
- Asthma dosing differs: For asthma patients, both 100/62.5/25 mcg and 200/62.5/25 mcg strengths are available, but this does NOT apply to COPD 1
Device Performance
Real-world data demonstrates that the Ellipta device delivers >80% of the nominal blister content across flow rates from 30-90 L/min, with near-complete dose emission occurring before reaching peak inspiratory flow 4. This means even patients with severe COPD who have reduced inspiratory capacity can achieve adequate drug delivery.